Paolo Moghetti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9072648/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The multifarious role of insulin in PCOS: From pathophysiology to therapeutic management. , 2022, , 39-54.		0
2	Clinical Value of Serum Levels of 11-Oxygenated Metabolites of Testosterone in Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2047-e2055.	3.6	9
3	Insulin resistance and PCOS: chicken or egg?. Journal of Endocrinological Investigation, 2021, 44, 233-244.	3.3	99
4	Walking for subjects with type 2 diabetes: a systematic review and joint AMD/SID/SISMES evidence-based practical guideline. Sport Sciences for Health, 2021, 17, 1-20.	1.3	1
5	Insulin-Mediated Substrate Use in Women With Different Phenotypes of PCOS: the Role of Androgens. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3414-e3425.	3.6	12
6	Circulating HMGB1 Levels Are Associated With Glucose Clamp-Derived Measures of Insulin Resistance in Women With PCOS. Journal of the Endocrine Society, 2021, 5, A738-A739.	0.2	0
7	Onset of Addison Disease appeared during the first trimester of a twin pregnancy: A case report. Clinical Case Reports (discontinued), 2021, 9, e03784.	0.5	2
8	Monitoring exercise intensity in diabetes: applicability of "heart rate-index―to estimate oxygen consumption during aerobic and resistance training. Journal of Endocrinological Investigation, 2020, 43, 623-630.	3.3	1
9	Walking for subjects with type 2 diabetes: A systematic review and joint AMD/SID/SISMES evidence-based practical guideline. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1882-1898.	2.6	32
10	Response to Comment on Olioso D, et al. "Effect of Aerobic and Resistance Training on Circulating Micro-RNA Expression Profile in Subjects with Type 2 Diabetes― Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1930-e1931.	3.6	0
11	Serum Androgens Are Independent Predictors of Insulin Clearance but Not of Insulin Secretion in Women With PCOS. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1981-e1989.	3.6	14
12	Current treatment for polycystic ovary syndrome: focus on adolescence. Minerva Pediatrica, 2020, 72, 288-311.	2.7	7
13	Diabetes Secondary to Endocrine Disorders and PCOS. Endocrinology, 2020, , 575-593.	0.1	0
14	Metabolic effect of breaks in sedentary time in subjects with type 2 diabetes. Current Opinion in Endocrine and Metabolic Research, 2019, 9, 40-44.	1.4	1
15	A Case Report of Insulinoma Relapse on Background Nesidioblastosis: A Rare Cause of Adult Hypoglycemia. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 773-778.	3.6	6
16	Effects of Aerobic and Resistance Training on Circulating Micro-RNA Expression Profile in Subjects With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1119-1130.	3.6	23
17	Association of free-living physical activity measures with metabolic phenotypes in type 2 diabetes at the time of diagnosis. The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS). Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 343-351.	2.6	5
18	The free androgen index is inaccurate in women when the SHBG concentration is low. Clinical Endocrinology, 2018, 88, 706-710.	2.4	22

#	Article	IF	CITATIONS
19	Effects of aerobic or resistance exercise training on cardiovascular autonomic function of subjects with type 2 diabetes: A pilot study. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 226-233.	2.6	26
20	Sex differences in the association of psychological status with measures of physical activity and sedentary behaviour in adults with type 2 diabetes. Acta Diabetologica, 2018, 55, 627-635.	2.5	7
21	Diabetes Secondary to Endocrine Disorders and PCOS. Endocrinology, 2018, , 1-19.	0.1	0
22	Role of Exercise in Vascular Function and Inflammatory Profile in Age-Related Obesity. Journal of Immunology Research, 2018, 2018, 1-9.	2.2	10
23	Reassessing Free-Testosterone Calculation by Liquid Chromatography–Tandem Mass Spectrometry Direct Equilibrium Dialysis. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2167-2174.	3.6	33
24	Diabetes Secondary to Endocrine Disorders and PCOS. Endocrinology, 2018, , 575-593.	0.1	0
25	Effects of Aerobic and Resistance Training on Circulating Micro-RNA Expression Profile in Subjects with Type 2 Diabetes. Diabetes, 2018, 67, 1718-P.	0.6	0
26	ls cardiorespiratory fitness impaired in PCOS women? A review of the literature. Journal of Endocrinological Investigation, 2017, 40, 463-469.	3.3	13
27	Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Human Reproduction, 2017, 32, 2515-2521.	0.9	90
28	Comparison between dual-energy X-ray absorptiometry and skinfold thickness in assessing body fat in overweigh/obese adult patients with type-2 diabetes. Scientific Reports, 2017, 7, 17424.	3.3	17
29	Physical Activity Patterns in Normal-Weight and Overweight/Obese Pregnant Women. PLoS ONE, 2016, 11, e0166254.	2.5	31
30	Metabolic Effects of Exercise. Frontiers of Hormone Research, 2016, 47, 44-57.	1.0	73
31	Implications of Androgen Assay Accuracy in the Phenotyping of Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 610-618.	3.6	51
32	Diabetic pregnancy outcomes in mothers treated with basal insulin lispro protamine suspension or NPH insulin: a multicenter retrospective Italian study. Journal of Maternal-Fetal and Neonatal Medicine, 2016, 29, 1061-1065.	1.5	9
33	VO2/PO Relationship In Type 2 Diabetic Subjects Medicine and Science in Sports and Exercise, 2016, 48, 607.	0.4	3
34	Insulin Resistance and Polycystic Ovary Syndrome. Current Pharmaceutical Design, 2016, 22, 5526-5534.	1.9	93
35	PCOS and Muscle Strength. Medicine and Science in Sports and Exercise, 2016, 48, 397.	0.4	0
36	Serum testosterone predicts cardiorespiratory fitness impairment in normalâ€weight women with polycystic ovary syndrome. Clinical Endocrinology, 2015, 83, 895-901.	2.4	7

Ραοιο Μοghetti

#	Article	IF	CITATIONS
37	Use of Insulin Lispro Protamine Suspension in Pregnancy. Advances in Therapy, 2015, 32, 888-905.	2.9	4
38	Glycemic Response To Acute Exercise In Type Ii Diabetes. Medicine and Science in Sports and Exercise, 2015, 47, 754.	0.4	0
39	Total Body Fat and Central Fat Mass Independently Predict Insulin Resistance but Not Hyperandrogenemia In Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 661-669.	3.6	54
40	How to manage the reproductive issues of PCOS: a 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology. Journal of Endocrinological Investigation, 2015, 38, 1025-1037.	3.3	18
41	Hemostatic and Fibrinolytic Abnormalities in Polycystic Ovary Syndrome. Seminars in Thrombosis and Hemostasis, 2014, 40, 600-618.	2.7	18
42	Plasma levels of pentraxin-3, an inflammatory protein involved in fertility, are reduced in women with polycystic ovary syndrome. European Journal of Endocrinology, 2014, 170, 401-409.	3.7	20
43	Relationships between cardiorespiratory fitness, metabolic control, and fat distribution in type 2 diabetes subjects. Acta Diabetologica, 2014, 51, 369-375.	2.5	12
44	Reply. Hepatology, 2014, 59, 352-352.	7.3	0
45	Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial). Hepatology, 2013, 58, 1287-1295.	7.3	275
46	Polycystic ovary syndrome as a diabetes risk factor. Expert Review of Endocrinology and Metabolism, 2013, 8, 485-487.	2.4	1
47	Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update, 2013, 19, 207-207.	10.8	6
48	Divergences in Insulin Resistance Between the Different Phenotypes of the Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E628-E637.	3.6	186
49	Metabolic Inflexibility Is a Feature of Women With Polycystic Ovary Syndrome and Is Associated With Both Insulin Resistance and Hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2581-2588.	3.6	36
50	Exercise for Hepatic Fat Accumulation in Type 2 Diabetic Subjects. International Journal of Endocrinology, 2013, 2013, 1-5.	1.5	6
51	Ten-week Whole-body Vibration Training Improves Body Composition and Muscle Strength in Obese Women. International Journal of Medical Sciences, 2013, 10, 307-311.	2.5	51
52	Managing Erectile Dysfunction in Heart Failure. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2013, 13, 125-134.	1.2	21
53	Low body weight and menstrual dysfunction are common findings in both elite and amateur ballet dancers. Journal of Endocrinological Investigation, 2013, 36, 343-6.	3.3	8
54	Hyperinsulinemia Amplifies GnRH Agonist Stimulated Ovarian Steroid Secretion in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1712-1719.	3.6	67

ΡΑΟΙΟ ΜΟGΗΕΤΤΙ

#	Article	IF	CITATIONS
55	Metabolic Effects of Aerobic Training and Resistance Training in Type 2 Diabetic Subjects. Diabetes Care, 2012, 35, 676-682.	8.6	177
56	Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update, 2012, 18, 146-170.	10.8	367
57	Differences in the Acute Effects of Aerobic and Resistance Exercise in Subjects with Type 2 Diabetes: Results from the RAED2 Randomized Trial. PLoS ONE, 2012, 7, e49937.	2.5	39
58	For what reasons should metformin be used in the management of polycystic ovary syndrome?. Journal of Endocrinological Investigation, 2012, 35, 87-9.	3.3	2
59	Insulin enhances ACTH-stimulated androgen and glucocorticoid metabolism in hyperandrogenic women. European Journal of Endocrinology, 2011, 164, 197-203.	3.7	44
60	Disorders of Coagulation and Hemostasis in Abdominal Obesity: Emerging Role of Fatty Liver. Seminars in Thrombosis and Hemostasis, 2010, 36, 041-048.	2.7	46
61	Supervised Walking Groups to Increase Physical Activity in Type 2 Diabetic Patients. Diabetes Care, 2010, 33, 2333-2335.	8.6	38
62	Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. European Journal of Endocrinology, 2009, 161, 737-745.	3.7	48
63	Chromosome Translocation Frequency after Radioiodine Thyroid Remnant Ablation: A Comparison between Recombinant Human Thyrotropin Stimulation and Prolonged Levothyroxine Withdrawal. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3472-3476.	3.6	40
64	Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. Journal of Endocrinological Investigation, 2009, 32, 695-700.	3.3	32
65	Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients. Clinical Endocrinology, 2008, 68, 481-484.	2.4	60
66	Circulating ghrelin levels in girls with central precocious puberty are reduced during treatment with LHRH analog. European Journal of Endocrinology, 2007, 156, 99-103.	3.7	14
67	Treatment of polycystic ovary syndrome with spironolactone plus licorice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 131, 61-67.	1.1	61
68	Effect of moderate aerobic exercise on sympatho-vagal balance in Type 2 diabetic patients. Diabetic Medicine, 2007, 24, 370-376.	2.3	50
69	Treatment of hirsutism and acne in hyperandrogenism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2006, 20, 221-234.	4.7	51
70	Use of antiandrogens as therapy for women with polycystic ovary syndrome. Fertility and Sterility, 2006, 86, S30-S31.	1.0	8
71	Effects of moderate-intensity exercise training on plasma biomarkers of inflammation and endothelial dysfunction in older patients with type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, 543-549.	2.6	130
72	Sorting the wheat from the chaff in macroprolactinaemia assessment. Annals of Clinical Biochemistry, 2006, 43, 89-89.	1.6	1

Ραοιο Μοςμεττι

#	Article	IF	CITATIONS
73	Clustering of Cardiovascular Risk Factors Associated With the Insulin Resistance Syndrome: Assessment by principal component analysis in young hyperandrogenic women. Diabetes Care, 2006, 29, 372-378.	8.6	23
74	Ovarian Suppression and Treatment of Hirsutism. , 2006, , 377-387.		2
75	A Study of the Hexose-6-Phosphate Dehydrogenase Gene R453Q and 11β-Hydroxysteroid Dehydrogenase Type 1 Gene 83557insA Polymorphisms in the Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4157-4162.	3.6	63
76	The M235T polymorphism of the angiotensinogen gene in women with polycystic ovary syndrome. Fertility and Sterility, 2005, 84, 1520-1521.	1.0	7
77	Association between the D19S884 marker at the insulin receptor gene locus and polycystic ovary syndrome. Fertility and Sterility, 2003, 79, 219-220.	1.0	49
78	Terapia della sindrome dell'ovaio policistico. L Endocrinologo, 2003, 4, 131-142.	0.0	0
79	Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism: Clinical and Experimental, 2003, 52, 862-867.	3.4	46
80	The Methionine 196 Arginine Polymorphism in Exon 6 of the TNF Receptor 2 Gene (TNFRSF1B) Is Associated with the Polycystic Ovary Syndrome and Hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3977-3983.	3.6	92
81	Insulin Resistance and the Persistence of Obesity from Childhood into Adulthood. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 71-76.	3.6	76
82	Insulin resistance: what is its role in the polycystic ovary syndrome?. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 444-450.	0.6	8
83	Advances in the treatment of polycystic ovary syndrome. Expert Opinion on Investigational Drugs, 2001, 10, 1631-1640.	4.1	4
84	Nuove prospettive terapeutiche della sindrome dell'ovaio policistico. L Endocrinologo, 2001, 2, 8-17.	0.0	0
85	Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care, 2000, 23, 45-50.	8.6	235
86	Power spectral analysis of heart rate in hypothyroidism. European Journal of Endocrinology, 2000, 143, 327-333.	3.7	39
87	Metformin Effects on Clinical Features, Endocrine and Metabolic Profiles, and Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled 6-Month Trial, followed by Open, Long-Term Clinical Evaluation ¹ . Journal of Clinical Endocrinology and Metabolism. 2000. 85, 139-146.	3.6	582
88	Antiandrogen Drugs Lower Serum Prostate-Specific Antigen (PSA) Levels in Hirsute Subjects: Evidence That Serum PSA Is a Marker of Androgen Action in Women. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 81-84.	3.6	30
89	Metformin Effects on Clinical Features, Endocrine and Metabolic Profiles, and Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled 6-Month Trial, followed by Open, Long-Term Clinical Evaluation. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 139-146.	3.6	437
90	Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double Blind, Placebo-Controlled Trial1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 89-94.	3.6	164

Ραοιο Μοςμεττι

#	Article	IF	CITATIONS
91	Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double Blind, Placebo-Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 89-94.	3.6	153
92	Spironolactone, But Not Flutamide, Administration Prevents Bone Loss in Hyperandrogenic Women Treated with Gonadotropin-Releasing Hormone Agonist1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1250-1254.	3.6	36
93	Leptin concentration in newborns' cord blood: relationship to gender and growth-regulating hormones. International Journal of Obesity, 1999, 23, 943-947.	3.4	32
94	Spironolactone, But Not Flutamide, Administration Prevents Bone Loss in Hyperandrogenic Women Treated with Gonadotropin-Releasing Hormone Agonist. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1250-1254.	3.6	20
95	Authors' Response: Spironolactone But Not Flutamide Administration Prevents Bone Loss in Hyperandrogenic Women Treated with Gonadotropin-Releasing Hormone Agonist. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4747b-4747.	3.6	0
96	New routes in the polycystic ovary syndrome labyrinth: A way out?. Journal of Endocrinological Investigation, 1998, 21, 648-655.	3.3	3
97	Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clinical Endocrinology, 1998, 48, 169-173.	2.4	74
98	Anti-TPO and anti-thyroglobulin antibodies or anti-TPO antibodies alone?. Clinical Endocrinology, 1997, 46, 235-236.	2.4	2
99	Outcome of Long-Term Treatment With the 5 alpha-Reductase Inhibitor Finasteride in Idiopathic Hirsutism. Obstetrical and Gynecological Survey, 1997, 52, 182-184.	0.4	0
100	Fasting plasma glucose and diabetes diagnosis. Clinica Chimica Acta, 1996, 252, 209-213.	1.1	4
101	Early changes in plasma glucagon and growth hormone response to oral glucose in experimental hyperthyroidism. Metabolism: Clinical and Experimental, 1996, 45, 1029-1033.	3.4	20
102	Outcome of long-term treatment with the 5α-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertility and Sterility, 1996, 66, 734-740.	1.0	77
103	Acute Effect of Insulin on Autonomic Regulation of the Cardiovascular System: A Study by Heart Rate Spectral Analysis. Diabetic Medicine, 1996, 13, 709-714.	2.3	37
104	The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women Journal of Clinical Endocrinology and Metabolism, 1996, 81, 952-960.	3.6	191
105	Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity Journal of Clinical Endocrinology and Metabolism, 1996, 81, 881-886.	3.6	154
106	Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 881-886.	3.6	134
107	The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 952-960.	3.6	151
108	Power spectral analysis of heart rate in hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2828-2835.	3.6	41

ΡΑΟΙΟ ΜΟGΗΕΤΤΙ

#	Article	IF	CITATIONS
109	Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior. Fertility and Sterility, 1995, 64, 511-517.	1.0	72
110	The Verona diabetes study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality. Diabetologia, 1995, 38, 318-325.	6.3	139
111	Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study. Diabetologia, 1995, 38, 672-679.	6.3	61
112	Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia, 1995, 38, 1122-1124.	6.3	150
113	Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads Journal of Clinical Endocrinology and Metabolism, 1995, 80, 836-840.	3.6	41
114	Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study. Diabetologia, 1995, 38, 672-679.	6.3	4
115	Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 836-840.	3.6	38
116	Clinical and Hormonal Effects of the 5 alpha-Reductase Inhibitor Finasteride in Idiopathic Hirsutism. Obstetrical and Gynecological Survey, 1995, 50, 290-293.	0.4	0
117	Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1115-1121.	3.6	56
118	Glucose counterregulatory response to acute hypoglycemia in hyperthyroid human subjects Journal of Clinical Endocrinology and Metabolism, 1994, 78, 169-173.	3.6	13
119	Glucose counterregulatory response to acute hypoglycemia in hyperthyroid human subjects. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 169-173.	3.6	15
120	Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1115-1121.	3.6	58
121	Mononuclear Leukocytes from Obese Patients with Type II Diabetes have Reduced Activity of Hexokinase, 6-Phosphofructokinase and Glucose-6-Phosphate Dehydrogenase. Hormone and Metabolic Research, 1993, 25, 160-164.	1.5	13
122	Influence of Body Fat and its Regional Localization on Risk Factors for Atherosclerosis in Young Men. American Journal of Epidemiology, 1992, 135, 1271-1278.	3.4	33
123	Studies on the mechanism of action of sulphonylureas in type II diabetic subjects: gliquidone. Journal of Endocrinological Investigation, 1992, 15, 1-11.	3.3	8
124	Detection of mutations in insulin receptor gene by denaturing gradient gel electrophoresis. Diabetes, 1992, 41, 408-415.	0.6	11
125	Plasma concentrations of glucagon during hyperglycemic clamp with or without somatostatin infusion in obese subjects. Acta Diabetologica Latina, 1990, 27, 309-314.	0.2	6
126	Enzymatic Activities Related to Intermediary Metabolism of Glucose in Circulating Mononuclear Cells from Obese Humans: Relationship to Enzyme Activity in Adipose Tissue. Enzyme, 1990, 43, 26-32.	0.7	5

Ραοιο Μοςμεττι

#	Article	IF	CITATIONS
127	Normal Inhibition by Somatostatin of Glucose-Stimulated B Cell Secretion in Obese Subjects. Hormone and Metabolic Research, 1990, 22, 584-588.	1.5	4
128	Plasma Concentrations of Growth Hormone during Hyperglycemic Clamp with or without Somatostatin Infusion in Obese Subjects*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1732-1734.	3.6	10
129	Glucose and insulin suppression of plasma free fatty acids in obese subjects with normal glucose tolerance or mild, newly diagnosed Type 2 (non-insulin-dependent) diabetes. Journal of Endocrinological Investigation, 1990, 13, 55-59.	3.3	7
130	Plasma C-peptide response to oral glucose load in hyperthyroidism. Journal of Endocrinological Investigation, 1990, 13, 555-557.	3.3	5
131	Estimates of <i>In Vivo</i> Insulin Action in Man: Comparison of Insulin Tolerance Tests with Euglycemic and Hyperglycemic Glucose Clamp Studies*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 374-378.	3.6	508
132	Differences in glucose metabolic enzyme activities in human adipose tissue from abdominal and gluteal regions. Metabolism: Clinical and Experimental, 1988, 37, 820-823.	3.4	4
133	Insulin receptors on circulating blood cells from patients with pancreatogenic diabetes: a comparison with type I diabetes and normal subjects. Journal of Endocrinological Investigation, 1987, 10, 311-319.	3.3	10
134	Effect of aging on growth hormone, ACTH and cortisol response to insulin-induced hypoglycemia in type I diabetes. Acta Diabetologica Latina, 1985, 22, 159-168.	0.2	2
135	Insulin Receptor on Monocytes from Patients with Acromegaly and Fasting Hyperglycemia*. Journal of Clinical Endocrinology and Metabolism, 1983, 56, 733-738.	3.6	23
136	Insulin Sensitivity, Binding, and Kinetics in Pancreatogenic and Type I Diabetes. Diabetes, 1982, 31, 346-355.	0.6	81
137	Insulin sensitivity, binding, and kinetics in pancreatogenic and type I diabetes. Diabetes, 1982, 31, 346-355.	0.6	20
138	Middle-distance running and DNA damage in diabetics. Journal of Laboratory and Precision Medicine, 0, 3, 18-18.	1.1	2
139	Comparison of plasma lipids changes after middle-distance running in euglycemic and diabetic subjects. Journal of Public Health and Emergency, 0, 3, 10-10.	4.4	3